The role of intralesional immunotherapy in Condyloma Acuminata
Department of Dermatology and Venereology, Dr. Saiful Anwar Hospital, Malang City, East Java, Indonesia.
Review Article
World Journal of Advanced Research and Reviews, 2023, 20(03), 1245–1262
Publication history:
Received on 05 November 2023; revised on 16 December 2023; accepted on 18 December 2023
Abstract:
Intralesional immunotherapy is one of the immunotherapy modalities that can be given to patients with condyloma acuminata (CA) with a high success rate both in inhibiting progression and preventing recurrence of genital warts. Intralesional immunotherapy regimens that are currently being studied are the use of vaccines and cytokines. Some of the antigens studied for use as therapy in genital warts include Candida albicans, measles, mumps and rubella (MMR), and Tuberculin/Purified Protein Derivate (PPD), Mycobacterium w, and Bacille Calmette-Guerin (BCG). Vaccines and cytokines work by inducing a delayed-type hypersensitivity response to warts tissue, both through cellular and humoral immune responses, mediated by CD8+ T lymphocytes, CD4+ T lymphocytes, B lymphocytes and regulatory T cells so that this can eliminate HPV virus infection in CA. This literature review aims to provide an understanding of the use of intralesional immunotherapy as an effective alternative therapy in CA.
Keywords:
Intralesional immunotherapy; Condyloma acuminata; Genital warts; Vaccines; Cytokines
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0